[go: up one dir, main page]

WO2019018841A3 - Compositions and methods for identification of combinatorial immunooncology therapeutics - Google Patents

Compositions and methods for identification of combinatorial immunooncology therapeutics Download PDF

Info

Publication number
WO2019018841A3
WO2019018841A3 PCT/US2018/043268 US2018043268W WO2019018841A3 WO 2019018841 A3 WO2019018841 A3 WO 2019018841A3 US 2018043268 W US2018043268 W US 2018043268W WO 2019018841 A3 WO2019018841 A3 WO 2019018841A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
combinatorial
identification
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/043268
Other languages
French (fr)
Other versions
WO2019018841A2 (en
Inventor
Dan Theodorescu
Mai Tu
Jason DUEX
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado System
University of Colorado Colorado Springs
Original Assignee
University of Colorado System
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado System, University of Colorado Colorado Springs filed Critical University of Colorado System
Publication of WO2019018841A2 publication Critical patent/WO2019018841A2/en
Publication of WO2019018841A3 publication Critical patent/WO2019018841A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure provides compositions and methods for improving immune-oncology therapies. In certain embodiments, the compositions and methods comprise a combination of a composition that inhibits the activity by reducing the expression level or blocking the function a target gene or protein, and a composition comprising an immune checkpoint blockade (ICB) reagent.
PCT/US2018/043268 2017-07-21 2018-07-23 Compositions and methods for identification of combinatorial immunooncology therapeutics Ceased WO2019018841A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762535669P 2017-07-21 2017-07-21
US62/535,669 2017-07-21
US201762569916P 2017-10-09 2017-10-09
US62/569,916 2017-10-09

Publications (2)

Publication Number Publication Date
WO2019018841A2 WO2019018841A2 (en) 2019-01-24
WO2019018841A3 true WO2019018841A3 (en) 2019-04-11

Family

ID=63143400

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/043268 Ceased WO2019018841A2 (en) 2017-07-21 2018-07-23 Compositions and methods for identification of combinatorial immunooncology therapeutics

Country Status (1)

Country Link
WO (1) WO2019018841A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ758316A (en) 2017-05-19 2025-08-29 Wuxi Biologics Shanghai Co Ltd Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4)
EP3781206A2 (en) 2018-04-20 2021-02-24 iOmx Therapeutics AG A 5-thiazolecarboxamide kinase inhibitor and uses thereof
EP3902833A2 (en) 2018-12-26 2021-11-03 City of Hope Activatable masked anti-ctla4 binding proteins
WO2021043289A1 (en) * 2019-09-06 2021-03-11 Biocytogen Pharmaceuticals (Beijing) Co., Ltd Genetically modified non-human animals with kit mutations
US11459567B2 (en) * 2020-06-24 2022-10-04 Patricia Virginia Elizalde Specific siRNA molecules, composition and use thereof for the treatment of triple negative breast cancer
WO2022056572A1 (en) * 2020-09-18 2022-03-24 Olivia Newton-John Cancer Research Institute Treatment of solid tumours
FR3130843A1 (en) * 2021-12-21 2023-06-23 Universite Claude Bernard Lyon 1 T-lymphocyte progenitor cell expressing a transgene of interest in a regulated manner

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHARLES GRAHAM ET AL: "Mechanisms Of Hypoxia-Induced Immune Escape In Cancer And Their Regulation By Nitric Oxide", REDOX BIOLOGY : AN OFFICIAL JOURNAL OF THE SOCIETY FOR FREE RADICAL BIOLOGY AND MEDICINE, AN OFFICIAL JOURNAL OF THE SOCIETY FOR FREE RADICAL RESEARCH-EUROPE, AN AFFILIATE JOURNAL OF THE INTERNATIONAL SOCIETY FOR FREE RADICAL RESEARCH (SFRRI), vol. 5, 1 August 2015 (2015-08-01), NL, pages 417, XP055523606, ISSN: 2213-2317, DOI: 10.1016/j.redox.2015.09.022 *
FRANCK MADOUX ET AL: "Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate", SCIENTIFIC REPORTS, vol. 6, no. 1, 1 December 2016 (2016-12-01), XP055523600, DOI: 10.1038/s41598-016-0013-4 *
KIMMO PORKKA ET AL: "An open-label, phase 1b, dose-escalation study (CA180-373) of dasatinib plus nivolumab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CM L)", JOURNAL OF CLINICAL ONCOLOGY, vol. 32, 1 January 2014 (2014-01-01), pages TPS7119, XP055318274 *
MASTERS: "Abstract 5016: Antitumor activity of anti-PD-1 in combination with tyrosine kinase inhibitors in a preclinical renal cell carcinoma model", AACR ANNUAL MEETING, vol. 74, 1 October 2014 (2014-10-01), pages 1 - 2, XP055255321, DOI: 10.1158/1538-7445.AM2014-5016 *
PARK JEONG A ET AL: "Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies", CANCER TREATMENT REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 58, 1 June 2017 (2017-06-01), pages 22 - 33, XP085133902, ISSN: 0305-7372, DOI: 10.1016/J.CTRV.2017.05.006 *

Also Published As

Publication number Publication date
WO2019018841A2 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
WO2019018841A3 (en) Compositions and methods for identification of combinatorial immunooncology therapeutics
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
WO2017059207A8 (en) Methods and reagents for analyzing protein-protein interfaces
HK1258509A1 (en) Gitr agonists
SG11202109423TA (en) Systems, compositions, and methods for target entity detection
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
MX364952B (en) Virus like particle comprising pd-1 antigen or pd-1 ligand antigen.
PH12018500233B1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
WO2016191643A3 (en) Tigit-binding agents and uses thereof
HK1250033A1 (en) Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
MX2017000083A (en) Platinum compounds, compositions, and uses thereof.
WO2016100807A3 (en) Human antibodies to influenza hemagglutinin
WO2016065349A8 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
MX2018003713A (en) Preventing, treating, and reducing (persistent) post-traumatic headache.
WO2015127134A3 (en) Complement component c5 antibodies
WO2018148486A8 (en) Anti-factor d antibodies and uses thereof
WO2016172551A3 (en) Methods of identifying bacteria comprising binding polypeptides
MX2019013751A (en) Pd-l1 antibody pharmaceutical composition and use thereof.
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
EP3403673A4 (en) COMPOSITION FOR PREVENTING OR IMPROVING THE FALL AND HAIR GRAY, AND USE THEREOF
MX2018012550A (en) Compositions and methods for the detection of host cell proteins.
MX2022006932A (en) Combinations of dgk inhibitors and checkpoint antagonists.
WO2017135791A8 (en) Anti-c-met antibodies and uses thereof
WO2017132746A8 (en) Ubiquitin variants and uses thereof as 53bp1 inhibitors
WO2014151982A3 (en) Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18752366

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18752366

Country of ref document: EP

Kind code of ref document: A2